Research demonstrates SPHK2's role in regulating triglyceride levels in the liver, indicating therapeutic potential for metabolic disorders.
SPHK2 attenuates hepatic steatosis by enzymatic-independently inhibiting ATGL ubiquitination and promoting triglyceride hydrolysis, indicating its therapeutic potential for MASLD.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: